These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 20920042)

  • 1. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance.
    Porter DW; Kerr BD; Flatt PR; Holscher C; Gault VA
    Diabetes Obes Metab; 2010 Oct; 12(10):891-9. PubMed ID: 20920042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.
    Porter WD; Flatt PR; Hölscher C; Gault VA
    Int J Obes (Lond); 2013 May; 37(5):678-84. PubMed ID: 22665137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actions of incretin metabolites on locomotor activity, cognitive function and in vivo hippocampal synaptic plasticity in high fat fed mice.
    Porter D; Faivre E; Flatt PR; Hölscher C; Gault VA
    Peptides; 2012 May; 35(1):1-8. PubMed ID: 22465882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
    Gault VA; Kerr BD; Harriott P; Flatt PR
    Clin Sci (Lond); 2011 Aug; 121(3):107-17. PubMed ID: 21332446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.
    Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM
    Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
    Noyan-Ashraf MH; Shikatani EA; Schuiki I; Mukovozov I; Wu J; Li RK; Volchuk A; Robinson LA; Billia F; Drucker DJ; Husain M
    Circulation; 2013 Jan; 127(1):74-85. PubMed ID: 23186644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet.
    Gault VA; Porter WD; Flatt PR; Hölscher C
    Int J Obes (Lond); 2010 Aug; 34(8):1341-4. PubMed ID: 20351729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
    Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
    Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1-derived nonapeptide GLP-1(28-36)amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice.
    Tomas E; Wood JA; Stanojevic V; Habener JF
    Regul Pept; 2011 Aug; 169(1-3):43-8. PubMed ID: 21549160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients.
    Flint A; Kapitza C; Hindsberger C; Zdravkovic M
    Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.
    Kerr BD; Flatt PR; Gault VA
    Biochem Pharmacol; 2010 Aug; 80(3):396-401. PubMed ID: 20417187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice.
    Porter DW; Irwin N; Flatt PR; Hölscher C; Gault VA
    Eur J Pharmacol; 2011 Jan; 650(2-3):688-93. PubMed ID: 21050845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
    Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
    Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
    Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice.
    Chen LN; Lyu J; Yang XF; Ji WJ; Yuan BX; Chen MX; Ma X; Wang B
    Int J Mol Med; 2013 Oct; 32(4):892-900. PubMed ID: 23877319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice.
    Lennox R; Porter DW; Flatt PR; Holscher C; Irwin N; Gault VA
    Neuropharmacology; 2014 Nov; 86():22-30. PubMed ID: 24998752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus.
    Vedtofte L; Bodvarsdottir TB; Gotfredsen CF; Karlsen AE; Knudsen LB; Heller RS
    Regul Pept; 2010 Feb; 160(1-3):106-14. PubMed ID: 20005262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
    Taylor A; Irwin N; McKillop AM; Flatt PR; Gault VA
    Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation GLP-1 therapy: an introduction to liraglutide.
    Repas T
    Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.